

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
09 March 2023 (09.03.2023)



(10) International Publication Number
WO 2023/031840 A1

(51) International Patent Classification:

A61K 31/505 (2006.01) A61K 9/28 (2006.01)
A61P 21/00 (2006.01) A61K 45/06 (2006.01)
A61K 47/00 (2006.01) A61K 9/20 (2006.01)

(21) International Application Number:

PCT/IB2022/058205

(22) International Filing Date:

01 September 2022 (01.09.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/240,444	03 September 2021 (03.09.2021)	US
63/282,363	23 November 2021 (23.11.2021)	US
63/304,106	28 January 2022 (28.01.2022)	US
63/353,866	21 June 2022 (21.06.2022)	US
63/369,008	21 July 2022 (21.07.2022)	US

(71) Applicant: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35,
4056 Basel (CH).

(72) Inventors: **BHATTACHARYA, Souvik**; 420 Thicket
Street, Weymouth, Massachusetts 02190 (US). **BIETH,
Bruno**; Novartis Pharma AG, Postfach, 4002 Basel (CH).
CENNI, Bruno; Novartis Pharma AG, Postfach, 4002
Basel (CH). **END, Peter**; Novartis Pharma AG, Postfach,
4002 Basel (CH). **GRAHAM, Gordon**; Novartis Pharma
AG, Postfach, 4002 Basel (CH). **JUHNKE, Michael**; F.
Hoffmann-La Roche AG, Building 10/Room O02, 4070
Basel (CH). **KARAN, Rajesh Singh**; Novartis Pharma AG,
Postfach, 4002 Basel (CH). **MANN, Allison Donna**; No-
vartis Pharmaceuticals Corporation, One Health Plaza, East
Hanover, New Jersey 07936-1080 (US). **PIGEOLET, Etie-
enne**; Novartis Pharma AG, Postfach, 4002 Basel (CH).
RAPP, Karin; Novartis Pharma AG, Postfach, 4002 Basel
(CH). **SIN, Kim-Hien**; Novartis Pharma AG, Postfach,
4002 Basel (CH). **YU, Huixin**; Novartis Pharma AG, Post-
fach, 4002 Basel (CH). **ZHANG, Ying**; Novartis Phar-
maceuticals Corporation, One Health Plaza, East Hanover,
New Jersey 07936-1080 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- in black and white; the international application as filed
contained color or greyscale and is available for download
from PATENTSCOPE

(54) Title: LOU064 FOR TREATING MULTIPLE SCLEROSIS

(57) Abstract: The invention concerns LOU064 or a pharmaceutically acceptable salt thereof for use in the effective treatment of multiple sclerosis (MS).

WO 2023/031840 A1